M. Oza

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

U. Wagner, A. Gottlieb, A. Orbai, 2017, The Lancet.

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study

D. Furst, K. Dao, M. Rosen, 2019, Arthritis care & research.

Acid Reflux: A Rare Adverse Effect of Duloxetine

Shubha Kollampare, Pinki Patel, M. Oza, 2023, Cureus.